Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scopolamine in Depression
NCT00369915Phase 2Terminated
- Sponsor
- National Institute of Mental Health
- Start
- Aug 2006
- Primary completion
- Jan 2013
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of scopolamine in major depressive disorder (MDD), bipolar disorder (BD), sponsored by National Institute of Mental Health. Started Aug 2006; status: terminated.
02
Drugs
scopolamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT00369915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00369915.